Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing

Hilmar Quentmeier1 *, Hans G. Drexler1, Vivien Hauer1, Roderick A. F. MacLeod1, Claudia Pommerenke1, Cord C. Uphoff1, Margarete Zaborski1, Mattias Berglund2, Claudia Enblad2☯, Rose-Marie Amini2☯

1 Department of Human and Animal Cell Lines, Leibniz-Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany, 2 Department of Immunology, Genetics and Pathology, Uppsala University and Uppsala University Hospital, Uppsala, Sweden

☯ These authors contributed equally to this work.
* hqu@dsmz.de

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma worldwide. We describe the establishment and molecular characteristics of the DLBCL cell line U-2946. This cell line was derived from a 52-year-old male with DLBCL. U-2946 cells carried the chromosomal translocation t(8;14) and strongly expressed MYC, but not the mature B-cell lymphoma associated oncogenes BCL2 and BCL6. Instead, U-2946 cells expressed the antiapoptotic BCL2 family member MCL1 which was highly amplified genomically (14n). MCL1 amplification is recurrent in DLBCL, especially in the activated B cell (ABC) variant. Results of microarray expression cluster analysis placed U-2946 together with ABC-, but apart from germinal center (GC)-type DLBCL cell lines. The 1q21.3 region including MCL1 was focally coamplified with a short region of 17p11.2 (also present at 14n). The MCL1 inhibitor A-1210477 triggered apoptosis in U-2946 (MCL1pos/BCL2neg) cells. In contrast to BCL2pos DLBCL cell lines, U-2946 did not respond to the BCL2 inhibitor ABT-263. In conclusion, the novel characteristics of cell line U-2946 renders it a unique model system to test the function of small molecule inhibitors, especially when constructing a panel of DLBCL cell lines expressing broad combinations of antiapoptotic BCL2-family members.

Introduction

Continuous cell lines have become indispensable tools in leukemia/lymphoma research. Self-renewing and transportable in the frozen state, cell lines provide unlimited supplies of cellular tumor material worldwide. Descendent from single cells of a patient’s tumor, they retain oncogenic aberrations and gene expression patterns characteristic of the primary tumor. Tumor congruence is a key reason why cell lines are used as models to study the function of aberrantly expressed genes or to test the efficiency of novel anti-cancer drugs [1,2].

Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma in adults. Various genes are recurrently affected by mutations and chromosomal aberrations therein, including the germinal center oncogenes BCL2, BCL6 and MYC [3]. Expression array analysis has identified two molecularly distinct forms of the tumor, termed germinal center (GC) and
activated B-cell (ABC) [4]. DLBCL-derived cell lines also show correspondingly distinct expression profiles allowing classification according to the GC- and ABC-scheme [5–9]. In contrast to GC-type DLBCL, ABC-type cells rely on the constitutive activation of the NF-kB pathway to block apoptosis [10]. Cell lines have been widely used to determine the effect of recurrent mutations or overexpressed genes on signaling pathways in ABC DLBCL and other lymphoma entities and to develop drugs for targeted therapies [5,7,10]. One important step in tumorigenesis is the loss of functional apoptosis, explaining why overexpression of antiapoptotic genes can contribute to tumorigenesis [11]. In DLBCL, the antiapoptotic genes \(BCL2\) and \(MCL1\) are recurrently overexpressed, as result of chromosomal translocations, amplification or other mechanisms [12–14]. We describe the establishment and molecular characteristics of the DLBCL-derived cell line U-2946. Due to an amplification on chr. 1q21.3, this cell line overexpresses \(MCL1\). Several DLBCL cell lines have been used to validate novel drugs targeting antiapoptotic \(BCL2\) family members [13–18]. We propose U-2946 as auspicious model cell line which shows the rare combination of \(MCL1\) positivity and \(BCL2\) negativity.

**Materials and Methods**

**Human cell lines**

Authenticated stocks of cell line U-2946 were grown in RPMI 1640 (Invitrogen, Darmstadt, Germany) containing 10% fetal bovine serum (FBS) (Sigma-Aldrich, Taufkirchen, Germany). Cell lines applied in this study are all held by the DSMZ—German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany (www.dsmz.de) or were supplied by the originators for research purpose. Detailed references and cultivation protocols have been described previously [19]. The \(BCL2\) family inhibitors ABT-263 and A-1210477 were obtained from Sell-eckchem (München, Germany).

**Cytogenetic analysis**

Cells were harvested and fixed as described previously [20]. Spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH) were performed as described previously [21]. Tile-path bacterial artificial chromosome (BAC) clones were sourced from BAC-PAC Resources (Children’s Hospital, Oakland, CA, USA), and SKY probes from Applied Spectral Imaging (Edingen, Germany). Probe selection was performed using the UCSC Genome Browser (https://genome-euro.ucsc.edu/) guided by the results of combined conventional cytogenetic, SKY and CytoScan copy number array data (see below). For colocalization experiments commercial chromosome painting probes were mixed 1:1 with labelled BACs. Probe preparation and labelling were as described previously [21]. Briefly, BAC clone DNA was labelled by nick translation with dUTPs contrastingly labelled with fluoros DY-495/547/590 purchased from Dyomics (Jena, Germany) and slide preparations counterstained with DAPI (4’6-Diamidino-2’-phenylindole dihydrochloride) in Vector antifade mountant (Biozol, Eching, Germany). Imaging and analysis were performed using an Axiosimager D1 microscope system equipped with an alpha-Plan Apochromat 100x objective (Zeiss, Goettingen, Germany) configured to a Spectral Imaging analysis system (Applied Spectral Imaging). For FISH, monochromatic fluor and DAPI signals were captured, merged and the pseudocolored images aligned automatically to generate reverse G-banding as described previously [21].

**Numerical aberrations**

CytoScan HD Array (Affymetrix, Santa Clara, CA, USA) hybridization analysis was performed to identify numerical aberrations. DNA was prepared using the Qiagen Gentra Puregene Kit
(Qiagen, Hilden, Germany). Data were analyzed using the Chromosome Analysis Suite software version 2.0.1.2 (Affymetrix).

**Cell surface marker analysis**

Immunophenotyping was conducted on a FACSCalibur (Becton Dickinson, Heidelberg, Germany). Antibodies (Abs) against CD3 (Leu4), CD5 (UCHT2), CD10 (H110a), CD19 (Leu12), CD20 (Leu16), CD34 (clone 581), CD37 (M-B371), CD38 (HIT2), CD138 (MI15) and HLA-DR (Tu39) were purchased from Becton Dickinson. Ab CD13 (My7) was from Beckman Coulter (Krefeld, Germany). Optimal dilutions of the Abs were determined with positive and negative control cell lines. FITC-labeled Abs against IgG, IgM, Ig kappa and Ig lambda were obtained from Southern Biotech/Biozol (Eching, Germany).

**Screening for immunoglobulin rearrangements and hypermutations**

Rearrangement of the immunoglobulin (Ig) heavy chain was determined by genomic PCR using primers described by van Dongen et al. [22]. The PCR was performed for 35 cycles at 60˚C annealing temperature. The level of Ig hypermutation was determined by sequencing the cloned PCR products. Ten clones were sequenced to screen for existence of U-2946 subclones.

**DNA microarray hybridization**

Five hundred ng total RNA were used for biotin labelling according to the 3´ IVT Express Kit (Affymetrix); 7.5 μg of biotinylated cDNA were fragmented and placed in a hybridization cocktail containing four biotinylated hybridization controls (BioB, BioC, BioD, and Cre). Samples were hybridized to an identical lot of Affymetrix GeneChip HG-U133 Plus 2.0 for 16 h at 45˚C. Steps for washing and SA-PE staining were processed on the fluidics station 450 using the recommended FS450 protocol (Affymetrix). Image analysis was performed on GCS3000 Scanner and GCOS1.2 Software Suite (Affymetrix). Data processing and analysis (probe summarisation, RMA-background correction and quantile normalization of spot intensities) were performed via R/Bioconductor using limma and affy packages [23–25].

**Quantitative real-time PCR analysis**

Quantitative PCR was performed on a 7500 Applied Biosystems real-time PCR system (Darmstadt, Germany). RNA was prepared using the RNeasy Mini kit (Qiagen). Reverse transcription was performed using the SuperScript II reverse transcriptase kit (Invitrogen, Karlsruhe, Germany). TaqMan probes (Applied Biosystems) were used to quantify human *BCL2* (Hs00153350_m1), *BCL6* (Hs00153368_m1), *MAP2K3* (Hs00177127_m1), *MCL1* Exon 1/2 (Hs03043899_m1), *MYC* exon 1/2 (Hs00905030_m1) and *MYC* exon 2/3 (Hs00153408_m1) expression levels with *TBP* as endogenous control. Relative expression levels were calculated using the ΔΔCt method.

Ploidy levels of *BCL2*, *MAP2K3* and *MCL1* were determined by genomic PCR applying the SYBR green assay system (Applied Biosystems) with *ABL1* as internal control and NC-NC as diploid reference cell line. DNA was prepared using the High pure PCR template preparation kit (Roche Life Science, Mannheim, Germany). The applied primers are listed in S1 Table.

**Western blot analysis**

Samples were prepared as described previously [26]. Anti BCL2 (1:500 dilution) and anti MCL1 Abs (1:250) were purchased from Becton Dickinson. Abs against the phosphorylated and unphosphorylated forms of p38 and MAP2K3 (1:10,000 each) and against BCL6 (1:1,000),
BCLXL (1:1,000) and MYC (1:2,000) were obtained from Cell Signaling Technology (Leiden, The Netherlands), the GAPDH mouse monoclonal Ab (mAb) (1:5,000) was from Abcam (Cambridge, UK). Specific bands on nitrocellulose membranes were visualized with the biotin/streptavidin-horseradish peroxidase system (GE Healthcare, Little Chalfont, UK) in combination with the “Renaissance Western Blot Chemoluminescence Reagent” protocol (Perkin Elmer, Waltham, MA, USA).

3H-thymidine uptake

Assays of 3H-thymidine incorporation were executed as follows: 1.25 x 10^4 cells (in 100 μl) were seeded in triplicate in 96-well flat-bottom microtiter cell culture plates. Inhibitors were added as 2x concentrated solution in a 100 μl volume. For the last 3 h of the incubation period, 1 μCi 3H-thymidine (Hartmann Analytic, Braunschweig, Germany) was added to each well.

Detection of apoptotic cells

Apoptotic cells were detected and quantified with the annexin-V/propidium iodide method using the TACS Annexin-V-FITC kit (R&D Systems, Wiesbaden, Germany) according to the manufacturer’s instructions. Binding of fluorescein isothiocyanate-labeled annexin-V and propidium iodide staining of the cells were determined by flow cytometry on the FACSCalibur (Becton Dickinson).

Results

Clinical history

The patient was a previously healthy man, age 52 years who sought medical care due to abdominal pain and tiredness. Computer tomography examination revealed an abdominal tumor. In July 1996 he underwent a right-sided hemicolectomy due to a tumor of the ascending colon. The tumor, 15 cm in diameter, removed macroscopically radically. Pathological examination showed DLBCL. Diagnostic work-up revealed lymphomatous engagement in the right testicle and in paratesticular tissue with a diameter of >10 cm, in lymph nodes and in the bone marrow (stage IVB). International Prognostic Index was retrospectively assigned to 3 (Stage IV, >1 extranodal site and elevated S-LDH (7 x upper normal limit)). At diagnosis he also had a palsy of the left N. abducens but examination of cerebrospinal fluid showed no signs of lymphoma and a CT of the brain was normal.

He was treated with VACOP-B [27]: a weekly schedule of alternating chemotherapy routinely used for aggressive lymphomas at our department at that time. He also received intrathecal injections of methotrexate 12.5 mg. At week 7 he had progressive disease and the treatment was changed to MIME [28], which was given for two courses before the patient progressed and received palliative radiotherapy. His disease progressed rapidly and he developed pleural effusion and leukemic lymphoma with a WBC count of > 100 x 10^9/l. The patient gave informed consent to use the pleural effusion for research including the possible establishment of a cell line. He died of progressive lymphoma three months after diagnosis. The overall picture of the lymphoma was an extremely aggressive disease with fast progression and very limited sensitivity to chemotherapy.

Large blast cells with the appearance of both immunoblasts and centroblasts grew in a diffuse and infiltrative pattern in the intestine. Several mitotic figures and apoptotic cells were present. Immunohistochemical stainings were performed and the lymphoma cells were positive for CD20, CD79a, CD10, BCL-6, MYC, p53 and negative for BCL-2, CD5, CD30, cyclin D1, SOX11 with a high proliferation index of Ki67. Partial expression of MUM1 and FOXP1
was detected. According to the WHO classification and update \[29,30\] the lymphoma would be classified as a DLBCL with a germinal-center derived phenotype according to the Hans et al algorithm (S1 Fig) [31,32]. In addition, MYC translocation was detected by in situ hybridization.

**Cell culture**

Tumor cells from pleural effusion were obtained by Ficoll-Isopaque (Lymphoprep, Nycomed) gradient separation and cultured in RPMI 1640 containing 10% of FBS, glutamine and antibiotics (100 IU/ml penicillin and 50 μg/ml streptomycin) at 37°C in 5% CO\(_2\) humidified environment. Cells were split every 72 h with an optimal density of 0.3 x 10\(^5\) cells/ml and a doubling time of 48 h. After one month, the cell line U-2946 was considered established and grew in continuous culture in RPMI 1640 with 10% FBS for another 2 months. U-2946 cells tested EBV-negative excluding a lymphoblastoid origin. May-Grünwald-Giemsa stain of the cell line is shown in S1 Fig.

**U-2946: immunoglobulin rearrangement and immunophenotype**

We tested the Ig rearrangement status of cell line U-2946 using previously described primers [22]. The cell line was found to carry an IGHV4-59 rearrangement with 6% hypermutation. Consistent with the patient’s tumor, U-2946 cells showed the typical immunophenotype of a B-lymphoma cell line (Table 1, S2 Fig).

**Karyotyping**

The consensus karyotype, performed using classical (Fig 1A) and spectral karyotyping (Fig 1B), together with FISH covering the IGH and MYC loci (Fig 1C–1G) was resolved to:

\[47<2n>XY, +7, \text{der}(9)t(2;9)(p25;p21), \text{der}(8)\text{inv}(8)(p22;q24), \text{der}(9)t(2;9)(p25;p22), \text{add}(17)(p11).\]

FISH revealed canonical juxtaposition of IGH and MYC, typical of B-cell neoplasms plus an additional non IGH rearrangement, der(8)t(8;8)(p23;q24), effecting copy number increase of the terminal 8q region just including PVT1, but excluding MYC.

Cytogenetic analysis also revealed a novel rearrangement, focal co-amplification of 1q21 and 17p11.2 replacing a deleted segment of chromosome 17p (Fig 1H–1M). The ca. 67 kbp–amplicon at 1q21 covered two loci (MCL1, ENSA), while that at 1p11 extending some 461 kbp covered four loci (USP22, DHRS7B, TMEM11, MAP2K3). Coamplification of gene pairs normally arises when a genomically remote gene pair, ectopically juxtaposed or fused by

| Table 1. Immunoprofile of patient and–derived cell line U-2946. |
|------------------|------------------|------------------|
| patient          | U-2946           | patient          | U-2946           |
| CD3              | neg              | CD37             | n.d.             |
| CD5              | neg              | CD38             | n.d.             |
| CD10             | pos              | CD138            | n.d.             |
| CD13             | n.d.             | HLA-DR           | n.d.             |
| CD19             | pos              | IgG              | n.d.             |
| CD20             | pos              | IgM              | n.d.             |
| CD22             | pos              | kappa            | n.d.             |
| CD34             | n.d.             | lambda           | n.d.             |

Expression of surface markers was assessed by flow cytometry with the appropriate isotype controls. pos, \(\geq\) 15% express antigen; neg, \(<\) 15% express antigen; n.d., not done.

doi:10.1371/journal.pone.0167599.t001
chromosome rearrangement is locally subjected to linear copy number amplification, e.g. following selection. Such copy number aberrations are hallmarks of oncogenes and are thought to arise by conferral of proliferation or antiapoptotic advantage.

U-2946 with ABC marker expression

Expression array analysis allows distinction between two forms of DLBCL, the GC and the ABC forms [4]. Based on five ABC marker genes and five GC markers [33], cell line U-2946 was assigned to the ABC group (Fig 2A). Unsupervised clustering of 19 DLBCL cell lines confirmed the ABC character of this cell line (Fig 2B).

BCL2, BCL6 and MYC

Mature B cell lymphomas often carry rearrangements and numerical aberrations leading to aberrant expression of BCL2, BCL6 and MYC. These aberrations can occur in the same tumors, which are then called “double-hit” or “triple-hit” lymphoma according to their aberration scores. Cell lines representing double-hit and triple-hit lymphomas have recently been reviewed in detail [35]. Amplifications or canonical translocations affecting chromosomes 18q21 (BCL2), 3q27 (BCL6) were not detected in U-2946 cells. As shown in Fig 1C–1G, MYC on 8q24 was fused to IGH on 14q32. In accordance with the genomic findings, cell line U-2946 was BCL2neg/BCL6low/MYCpos (Fig 3A and 3B). 5´RACE revealed that the MYC transcript began in intron 1/2, not in exon 1 (data not shown). Accordingly qRT-PCR showed MYC transcript in exon 2 but not in exon 1 suggesting (i) that the genomic break was located in intron 1/2, and (ii) that translation started with the alternative ATG start codon in exon 2 and not with the “internal ribosome entry site” (IRES)-mediated CTG codon in exon 1 (Fig 3A).

Numerical aberrations are responsible for aberrant gene expression in U-2946

To find genes conspicuously expressed in U-2946, we compared expression array data of this cell line with those of 55 other certified B-lymphoma cell lines spanning the whole spectrum of B-NHL. Thirty-nine of the 46 marker genes (85%) were upregulated in U-2946; another 7 genes (15%) lay below the average of B-lymphoma cell lines (S3 Fig). High density genomic array analyses revealed that 6/7 underexpressed genes mapped to haploid regions (S2 Table). Five genes were amplified, all of them overexpressed (S2 Table). Thus, we found an almost perfect correlation between deletion and lack of expression on the one side, and amplification and overexpression on the other. The most prominent amplifications were at regions 1q21.3 (6n) (Fig 1N) and 17p11.2 (4n-10n) (Fig 1O). The amplified genes are listed in S3 Table.
Fig 2. U-2946: an ABC DLBCL cell line. A) heatmap of ABC/GC gene expression, data from expression array analysis. The majority of ten ABC and GC markers described by Ruminy et al. [33] class U-2946 as ABC DLBCL cell line. B) Applying the same set of marker genes, cell line U-2946 clustered together with described ABC DLBCL cell lines (red), not with GC cell lines (green) [5–9]. Cell line NU-DHL-1 (orange) was discordantly categorized by different authors [6,8]. We showed that subclone R1 of the ABC cell line U-2932 highly expressed various GC markers, absent from subclone R2 [34].

doi:10.1371/journal.pone.0167599.g002

Fig 3. Expression of BCL2, BCL6, BCLXL, MAP2K3, MCL1, and MYC in DLBCL cell lines. A) qRT-PCR and B) Western blot analysis was performed to assess the expression of oncogenes in U-2946 and other DLBCL cell lines. The bars in A) indicate means with standard deviation (n = 3). The ct values for BCL-W in qRT-PCR were high (>30) in all cell lines tested explaining absence of specific bands in Western blot analysis (not shown). Note the high-level expression of MCL1 (red) in cell lines U-2946 and U-2932.

doi:10.1371/journal.pone.0167599.g003
MAP2K3: amplified but inactive

Located on 17p11.2, MAP2K3 (MEK3) was amplified in cell line U-2946 (Fig 1O, S3 Table). Amplification of the gene was accompanied by overexpression of MAP2K3, at the mRNA and protein levels (Fig 3A and 3B). This kinase is known to activate the p38 MAPK pathway [36]. Sequencing of MAP2K3 cDNA showed that the gene was not mutated. Nevertheless, cell lines with low expression of MAP2K3 showed the same p38 MAPK phosphorylation level as cell line U-2946 (Fig 4). Thus, MAP2K3 was highly expressed in cell line U-2946, but did not aberrantly trigger the p38 MAPK pathway.

Fig 4. Phosphorylation of the MAP2K3/p38 pathway. Expression and phosphorylation of MAP2K3 and p38 in U-2946 and five other DLBCL cell lines was determined by Western blot analysis. Note that overexpression of MAP2K3 was not accompanied by high phosphorylation of the MAP2K3 target in cell line U-2946.

doi:10.1371/journal.pone.0167599.g004
MCL1 amplified on der chr17

Like BCL2, MCL1 is an antiapoptotic gene and recurrently overexpressed in DLBCL [13,14]. Accordingly, the 1q21 region including the MCL1 locus is recurrently amplified in DLBCL [37]. A positive correlation of MCL1 amplification and gene expression was specifically observed in ABC DLBCL [14]. Thus 1q21.3 amplification (including the MCL1 gene locus) is consistent with the ABC character proposed here for cell line U-2946 (Fig 1N, S3 Table). FISH analysis revealed that MCL1 was translocated to chr17, specifically to the amplified region on 17p11.2 including MAP2K3 (Fig 1H–1M).

To elucidate whether MCL1 amplification might correlate with the gene’s overexpression, we performed qRT-PCR and Western blot analysis for U-2946 in comparison with other DLBCL cell lines (Fig 3A and 3B). Cell line U-2946 was MCL1pos/BCL2neg. All other cell lines showed different combinations of MCL1 and BCL2 expression (y3A and 3B). Overexpression of both genes was always accompanied by genomic amplification, except in OCI-LY1, where we observed BCL2 mRNA overexpression without genomic amplification (S4 Fig). This cell line is known to carry the t(14;18) effecting IGH/BCL2 juxtaposition, another well-described cause of aberrant BCL2 expression [12,38].

MCL1 with antiapoptotic function in cell line U-2946

To find out whether MCL1 and BCL2 were critical for cell survival in our DLBCL cell lines, we incubated the cell lines with inhibitors of MCL1 (A-1210477) or BCL2, BCL-XL and BCL-W (ABT-263). The MCL1 inhibitor (A-1210477, 7.5 μM) substantially reduced 3H-thymidine uptake and triggered apoptosis in the MCL1pos cell line U-2946, while MCL1neg cell lines were not affected (Figs 5A and 6). All BCL2pos cell lines (OCI-LY1, RI-1, U-2932) were responsive to low doses of the BCL2 inhibitor (Figs 5B and 6). Noteworthingly, the pharmacological MCL1 inhibitor left the MCL1pos/BCL2pos cell line U-2932 unperturbed. Even in the presence of low concentrations of the BCL2 inhibitor (50 nM ABT-263), the MCL1 inhibitor (7.5 μM A-1219477) did not have any effect on U-2932 cells, suggesting that BCL2 was dominant over MCL1 in the U-2932 cell system (Fig 6 and S5 Fig).

Discussion

Cell line U-2946 was established in 1996 from a 52-year-old male patient with terminal DLBCL following standard chemotherapy. Immunohistochemical staining classified the tumor into a GC-derived phenotype according to the Hans classification [39]. However, the only data published so far on cell line U-2946 describe the strong expression of ZAP70 and PKC-β II, a feature occurring in the more aggressive clinical form of non-GC DLBCL [39]. Expression profiling confirmed that ZAP70 levels were much higher in U-2946 than in the average of 56 B-lymphoma cell lines tested. Also consistent with the non-GC character of this cell line, U-2946 clustered together with other ABC DLBCL cell lines, as evidenced by gene expression analysis, applying a short-list of five ABC marker genes and five GC markers.

Translocations and/or numerical aberrations affecting the germinatal center oncogenes BCL2 and BCL6 were not detected in U-2946 cells. FISH revealed the canonical juxtaposition of IGH and MYC, leading to overexpression of the oncogene in this cell line. The most prominent numerical abnormalities in U-2946 were amplifications on chromosomes 1q21.3 and 17p11.2. Both sites were coamplified on a derivative chromosome 17. MAP2K3, on 17p21.3, and MCL1, located on 1q21.3, were highly expressed. The MAP2K3 overexpression did not lead to unusual phosphorylation of the downstream target p38 MAPK, suggesting that amplification of the MAP2K3 was a passenger or helper mutation and that amplification of MCL1 might be the true oncogenic event. MCL1 is frequently expressed in DLBCL, in the ABC subtype more
Cell Line U-2946: Model for MCL1 Inhibitor Testing

A

A-1210477

3H-thymidine uptake

0% 20% 40% 60% 80% 100% 120% 140%

0 1.9 3.8 7.5 15 30 (µM)

RI-1
OCI-LY1
U-2932
U-2946

B

ABT-263

3H-thymidine uptake

0% 20% 40% 60% 80% 100% 120%

0 0.01 0.1 1 10 (µM)

RI-1
OCI-LY1
U-2932
U-2946
often than in GC and also at higher expression levels, which correlates with higher frequency of 1q21 amplification in ABC cases [13,14]. MCL1 rescues cells from apoptosis by binding and sequestering proapoptotic BCL2-family members. Small-molecule inhibitors, developed to trigger apoptosis, have been tested in cell lines expressing antiapoptotic BCL2-family proteins [13,15–18]. Recently, it has been shown that DLBCL can be divided into BCL2-dependent and MCL1-dependent groups [40]. Cell line U-2946 expresses MCL1, but not BCL2 and only low levels of BCL-XL. Accordingly, apoptosis was induced by the MCL1 inhibitor A-1210477, while the BCL2/BCL-XL inhibitor ABT-263 (Navitoclax) had no effect. Other DLBCL cell lines expressed BCL2 and responded to ABT-263. U-2932 was one of these BCL2pos cell lines. This
cell line also expressed MCL1, but did not respond to the MCL1 inhibitor. Even with low doses of the BCL2 inhibitor, A-1210477 was inefficient which suggests that the effect of BCL2 is dominant over MCL1, at least in this cell system.

We conclude that the MCL1\textsuperscript{pos}/BCL2\textsuperscript{neg} cell line U-2946 promises to be a valuable model for inhibitor studies, useful especially in combination with cell lines expressing other antiapoptotic BCL2 family members. Cell line U-2946 will be available from the public repository DSMZ (www.dsmz.de).

Conclusions

We describe the establishment and characteristics of the DLBCL cell line U-2946. According to gene expression data, the cell line clusters together with ABC DLBCL cell lines. The cell line carries an amplification of the antiapoptotic BCL2 family member MCL1. The MCL1 chromosomal region (1q21.3) was involved in a translocation to chromosome 17. The amplified MCL1 gene is highly expressed in the cell line (MCL1\textsuperscript{pos}/BCL2\textsuperscript{pos}). Inhibitor experiments revealed the importance of MCL1 for growth and survival of U-2946 cells. Cell line U-2946 will prove to be an important model system for the functional analysis of small BCL2-family inhibitors, especially in a panel of certified DLBCL cell lines showing other MCL1 and BCL2 expression profiles.

Supporting Information

S1 Fig. Stainings of lymphoma cells and cell line. A-E) Immunohistochemical stainings of lymphoma cells. Positive: BCL6 (A), CD10 (B), CD20 (C), CD79a, FOXP1, MUM1 (partial), MYC (D), p53 and negative: BCL2 (E), CD3, CD5, CD30, cyclin D1. (F) May-Grünwald-Giemsa stain of cell line U-2946.

S2 Fig. Immunophenotype of cell line U-2946. Cells were stained with Abs against the antigens indicated and analyzed by flow cytometry.

S3 Fig. U-2946 vs 55 B-lymphoma cell lines—the top differentially expressed genes. The 47 genes with strongest expression differences between U-2946 and median of 55 B-lymphoma cell lines in relation to variance (IQR, interquartile range)—highest differences on the left. Data base on expression array analyses. Red dots, cell line U-2946.

S4 Fig. Ploidy and gene expression. Quantitative genomic PCR (upper) and qRT-PCR (lower) detecting correlation between amplification and RNA expression in BCL2, MAP2K3 and MCL1. The bars indicate means with standard deviation (n = 3). NC-NC as diploid reference cell line for genomic PCR.

S5 Fig. MCL1 and BCL2 inhibition. 3H-thymidine uptake after 48 h. The MCL1 inhibitor A-1210477 (7.5 \textmu M) inhibits growth of the MCL1\textsuperscript{pos}/BCL2\textsuperscript{pos} cell line U-2946, but has no effect on the MCL1\textsuperscript{pos}/BCL2\textsuperscript{pos} cell line U-2932 –neither alone nor together with suboptimal doses of the BCL2 inhibitor ABT-263 (50 nM). The bars indicate means with standard deviation (n = 3).

S1 Table. Primers for genomic PCR.
S2 Table. 46 top outliers in U-2946 vs. 55 B-lymphoma cell lines. Outliers are listed according to chromosomal position. Note the perfect correlation between genomic imbalances and expression in cell line U-2946, 6/6 hemiploid genes (black and bold) being repressed, 5/5 amplified genes (red and bold) being overexpressed. Up, higher than average; down, lower than average.

(XLSX)

S3 Table. Amplified genes in cell line U-2946. Amplified genes on 1q21.3 are listed from centromere to telomere, genes on 17p11.2 from telomere to centromere. Bold: strongly expressed genes as assessed by expression array analysis.

(XLSX)

Author Contributions
Conceptualization: HQ HGD GE RMA.
Formal analysis: CP.
Investigation: HQ HGD VH RML CP MZ MB GE RMA.
Methodology: HQ RML GE RMA CCU.
Resources: HGD MB GE RMA.
Software: CP.
Validation: HQ VH RML CP MZ RMA.
Visualization: HQ RML RMA.
Writing – original draft: HQ.
Writing – review & editing: HGD RML GE RMA.

References
1. Drexler HG. Establishment and culture of leukemia-lymphoma cell lines. In: Cree I editor. Cancer Cell Culture: Methods and Protocols, 2nd edition. Springer, Berlin; 2011. pp. 181–200.
2. Drexler HG, Quentmeier H, MacLeod RAF. Cell line models of leukemia. Drug Discovery Today—Disease Models 2005; 2:51–56.
3. Pasqualucci L, Dalla-Favera R. SnapShot: diffuse large B cell lymphoma. Cancer Cell 2014; 25:132. doi: 10.1016/j.ccr.2013.12.012 PMID: 24434215
4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503–511. doi: 10.1038/35000501 PMID: 10676951
5. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463:88–92. doi: 10.1038/nature08638 PMID: 20054396
6. Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007; 204:633–643. doi: 10.1084/jem.20062041 PMID: 17353667
7. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470:115–118. doi: 10.1038/nature09671 PMID: 21179087
8. Laursen MB, Falgreen S, Boedker JS, Schmitz A, Kjeldsen MK, Soerensen S, et al. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. Exp Hematol. 2014; 42:927–938. doi: 10.1016/j.exphem.2014.07.263 PMID: 25072621
9. Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 2015; 29:1578–1586. doi: 10.1038/leu.2015.48 PMID: 25708834

10. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med; 194:1861–1874. PMID: 11748286

11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646.674. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230

12. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997; 90:1168–1174. PMID: 9242549

13. Li L, Pontomppiat P, Tutan T, Kendrick SL, Park S, Persky DO et al. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia 2015; 29:1702–1712. doi: 10.1038/leu.2015.99 PMID: 25882699

14. Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, Madle H, et al. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia 2013; 27:1381–1390. doi: 10.1038/leu.2012.367 PMID: 23257783

15. Souers AJ, Lebody ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Med. 2013; 19:202–208. doi: 10.1038/nm.3048 PMID: 23291630

16. Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, et al. Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer Journal 2015; 5:e368. doi: 10.1038/bcj.2015.88 PMID: 26565405

17. Lebody JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death and Disease 2015; 6:e1590. doi: 10.1038/cddis.2014.561 PMID: 25590800

18. Klonova M, Andera L, Branzina J, Svadlenka J, Benesova S, Soukup J, et al. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL1- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. Clin Cancer Res. 2016; 22:1138–1149. doi: 10.1158/1078-0432.CCR-15-1191 PMID: 26467384

19. Drexler HG. Guide to leukemia-lymphoma cell lines. 2nd Edn., Braunschweig, 2010.

20. MacLeod RA, Kaufmann M, Drexler HG. Cytogenetic harvesting of commonly unused tumour cell lines. Nat Protoc. 2007; 2:372–382. doi: 10.1038/nprot.2007.29 PMID: 17406598

21. van Dongen JJM, Langerak AW, Brüggemann M, Evans PAS, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspsect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003; 17:2257–2317. doi: 10.1038/sj.leu.2403202 PMID: 14671650

22. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43:e47. doi: 10.1093/nar/gkv007 PMID: 25605792

23. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20:307–315. doi: 10.1093/bioinformatics/btg405 PMID: 14960456

24. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alert the interpretation of GeneChip data. Nucleic Acids Res. 2005; 33:e175. doi: 10.1093/nar/gni179 PMID: 16284200

25. Quintmeier H, Schneider B, Röhrs S, Romani J, Zaborski M, MacLeod RAf, et al. SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol. 2009; 2:3. doi: 10.1186/1756-8722-2-3 PMID: 19166587

26. Pichert G, Peters J, Stahel RA, Dommann C, Joss R, Gebbers JO, et al. Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin’s lymphoma: clinical results and analysis of prognostic factors. Ann Oncol. 1992; 3:645–649. PMID: 1280460

27. Cabanillas F, Hagemeister FB, McLaughlin P, Velasques WS, Riggis S, Fuller L, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol. 1987; 5:407–412. doi: 10.1200/jco.1987.5.3.407 PMID: 3819806
29. Swerdlow SH, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of hematopoietic and lymphoid tissues. In: Bosman FT, Jaffe ES, Lakhan SR, Ohgaki H, eds. World Health Organization Classification of Tumours. Lyon, France: IARC; 2008.

30. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stain H, Siebert R, et al. The 2016 revision of the World health organization classification of lymphoid neoplasms. Blood 2016; 127:2375–2390. doi: 10.1182/blood-2016-01-643569 PMID: 26980727

31. Hans CP, Weisenburger DD, Greiner TC, Greiner TC, Gascoyne RD, Delabie J, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275–282. doi: 10.1182/blood-2003-05-1545 PMID: 14504078

32. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the international DLBCL rituximab-CHOP consortium program study. Leukemia 2012; 26:2103–2113. doi: 10.1038/leu.2012.83 PMID: 22437443

33. Ruminy P, Mareschal S, Bagacean C, Rainville V, Leroy K, Jais JP, et al. Accurate classification of GCB/ABC and MYC/BCL2 diffuse large B-cell lymphoma with a 14 genes expression signature and a simple and robust RT-MLPA assay. Blood 2013; 122(21):84.

34. Ding J, Dirks WG, Ehrentraut S, Geffers R, MacLeod R, MacLeod RAF, et al. BCL6 –regulated by AhR/ARNT and wild-type MEF2B –drives expression of germinal center markers MYBL1 and LMO2. Haematologica 2015; 100:6.

35. Drexler HG, Eberth S, Nagel S, MacLeod RAF. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas. Leukemia Lymphoma 2016; 57:1015–1020. doi: 10.3109/10428194.2015.1108414 PMID: 26727417

36. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999; 5:439–447. PMID: 10498912

37. Palanisamy N, Abou-Ella AA, Chaganti SR, Houldsworth J, Offit K, Louie DC, et al. Similar patterns of genomic alterations characterize primary mediastinal large B-cell lymphoma and diffuse large B cell lymphoma. Genes, Chromosomes & Cancer 2002; 33:114–122.

38. Farrugia MM, Duan LJ, Reis MD, Ngan BY, Berinstein NL. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. Blood 1994; 83:191–198. PMID: 8274734

39. Fridberg M, Servin A, Anagnostaki L, Linderoth J, Berglund M, Soederberg O, et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-b II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leukemia Lymphoma 2007; 48:2221–2232. doi: 10.1080/1042819070136443 PMID: 17926183

40. Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, et al. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. Clin Cancer Res. 2016; 22:1138–1149. doi: 10.1158/1078-0432.CCR-15-1191 PMID: 26467384